TABLE 1.
Patient characteristics
| Variable | N | % | |
|---|---|---|---|
| Study cohort | 172 | 100 | |
| Median age (range) | 61.3 (23‐86) years | ||
| NLRC5 | WT | 116/172 a | 67.4 |
| SNV | 11/172 | 6.4 | |
| CNL | 11/172 | 6.4 | |
| Methylated | 39/132 | 30 | |
| Sex | Male | 85/172 | 49.4 |
| Ann Arbor stage | I‐II | 37/172 | 21.5 |
| III‐IV | 135/172 | 78.5 | |
| ECOG | >1 | 13/172 | 7.6 |
| FLIPI | 1‐2 | 96/172 | 55.8 |
| 3 | 75/172 | 43.6 | |
| Treatment | No treatment | 20/172 | 11.6 |
| R‐CHOP | 79/172 | 45.9 | |
| R‐CVP | 37/172 | 21.5 | |
| B‐R | 13/172 | 7.6 | |
| Otherb | 6/172 | 3.5 | |
| Radiation alone | 17/172 | 9.8 | |
| POD24 | 40/172c | 23.2 | |
| Extranodal site involvement | 62/172 d | 36.0 | |
| Bone marrow involvement | 76/172 d | 44.2 | |
| Presence of B symptoms | 35/172 d | 20.3 | |
| Median follow‐up | 5.1 years | ||
Abbreviations: B, bendamustine; CHOP, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone; CNL, copy number loss; CVP, cyclophosphamide, vincristine sulfate, and prednisone; ECOG, Eastern European Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index; POD24, progression of disease within 24 months.; R, rituximab; SNV, single nucleotide variant; WT, wild type.
a
Methylation status not known in 40 cases.
b
CHOP + Etoposide, R‐Chlorambucil, R‐Monotherapy.
c
Missing data for 10 cases.
d
Missing data for one case.